ライブ
FierceBiotechAs China biotech crackdown calls reverberate in Washington, the pushback gets louder, tooEndpoints NewsNovo Holdings backs European fund; Alnylam sends second obesity drug into clinicFierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3Thermo FisherThermo Fisher Introduces M Series Centrifuges - Contract PharmaLonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila TimesLonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila TimesEndpoints NewsParabilis Medicines charts $413M IPO to back peptide pipelineFierceBiotechInnovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADCPharmaVoiceHouse bill aims to crack down on China biotech dealsPharmaVoicePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?FierceBiotechMedline earns FDA warning letter ire for repeated toxic bacteria problemsFierceBiotechFrom business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’
Endpoints News 2026年2月27日

Generate:Biomedicines raises $400M IPO, CEO talks about AI's future in drug design

Generate:Biomedicines raises $400M IPO, CEO talks about AI's future in drug design

原文
本文は利用できません。元の情報源をご確認ください。